Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone
https://finance.yahoo.com/news/imfinzi-durvalumab-plus-chemotherapy-approved-110000689.html
Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone
https://finance.yahoo.com/news/imfinzi-durvalumab-plus-chemotherapy-approved-110000689.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.